1. Home
  2. PLGO vs SRPT Comparison

PLGO vs SRPT Comparison

Compare PLGO & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pelagos Insurance Capital Limited Common Shares

PLGO

Pelagos Insurance Capital Limited Common Shares

N/A

Current Price

$28.85

Market Cap

2.0B

Sector

Finance

ML Signal

N/A

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

N/A

Current Price

$16.08

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLGO
SRPT
Founded
2014
1980
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
2015
2000

Fundamental Metrics

Financial Performance
Metric
PLGO
SRPT
Price
$28.85
$16.08
Analyst Decision
Hold
Hold
Analyst Count
9
24
Target Price
★ $26.50
$21.77
AVG Volume (30 Days)
361.7K
★ 2.2M
Earning Date
11-11-2026
11-05-2026
Dividend Yield
★ 3.05%
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ 2.78
Revenue
N/A
★ $2,198,237,000.00
Revenue This Year
$5.49
N/A
Revenue Next Year
$5.68
N/A
P/E Ratio
★ N/A
$5.78
Revenue Growth
N/A
N/A
52 Week Low
$20.85
$14.68
52 Week High
$29.62
$24.68

Technical Indicators

Market Signals
Indicator
PLGO
SRPT
Relative Strength Index (RSI) 73.48 37.20
Support Level $23.95 $15.19
Resistance Level N/A $18.26
Average True Range (ATR) 0.74 0.92
MACD 0.20 -0.25
Stochastic Oscillator 79.57 8.92

Price Performance

Historical Comparison
PLGO
SRPT

About PLGO Pelagos Insurance Capital Limited Common Shares

Pelagos Insurance Capital Ltd operates in the specialty insurance and reinsurance sector. Its activities include capital allocation, risk selection, and the deployment of capital through underwriting partnerships across insurance and reinsurance markets. The company manages a diversified portfolio and works with underwriting partners to provide insurance and reinsurance solutions to clients and brokers.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: